Antibody-guided in vivo imaging for early detection of mammary gland tumors

Translational Oncology

Volumn 9, Issue 4, 2016, Pages 295-305

  Moore, Laura Jeffords ^a   Roy, Lopamudra Das ^a,b   Zhou, Ru ^a   Grover, Priyanka ^a   Wu, Shu Ta ^a   Curry, Jennifer M ^a   Dillon, Lloye M ^a,b   Puri, Priya M ^a   Yazdanifar, Mahboubeh ^a   Puri, Rahul ^b   Mukherjee, Pinku ^a,b   Dréau, Didier ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b 243 Bioinformatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TAB 004; MUCIN 1; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST HYPERPLASIA; CANCER GROWTH; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PROSTHESIS IMPLANTATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

EID: 84983416499     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.05.001     Document Type: Article

References (48)

1. Campone M, Valo I, Jezequel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, and Guette C (2015). Prediction of recurrence and survival for triple-negative breast cancer by a protein signature in tissue samples. Mol Cell Proteomics 14, 2936–2946.
2. Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, Brawley OW, and Gansler T (2015). Cancer statistics: breast cancer in situ. CA Cancer J Clin 65, 481–495.
3. DeSantis C, Ma J, Bryan L, and Jemal A (2014). Breast cancer statistics, 2013. CA Cancer J Clin 64, 52–62.
4. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YT, Walter LC, Church TR, Flowers CR, and LaMonte SJ, et al (2015). Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314, 1599–1614.
5. Gilbert FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY, and Purushothaman H, et al (2015). The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme—a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess 19, 1–136[i-xxv].
6. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, and Miglioretti DL (2015). Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 162, 673–681.
7. Scheel JR, Lee JM, Sprague BL, Lee CI, and Lehman CD (2015). Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. Am J Obstet Gynecol 212, 9–17.
8. Moshina N, Ursin G, Hoff SR, Akslen LA, Roman M, Sebuodegard S, and Hofvind S (2015). Mammographic density and histopathologic characteristics of screen-detected tumors in the Norwegian Breast Cancer Screening Program. Acta Radiol Open 4. http://dx.doi.org/10.1177/2058460115604340.
9. Beatson RE, Taylor-Papadimitriou J, and Burchell JM (2010). MUC1 immunotherapy. Immunotherapy 2, 305–327.
10. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, and Gendler SJ (2003). Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26, 47–62.
11. Ideo H, Hinoda Y, Sakai K, Hoshi I, Yamamoto S, Oka M, Maeda K, Maeda N, Hazama S, and Amano J, et al (2015). Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer. Int J Cancer 137, 1652–1660.
12. Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H, and Baar J (2013). MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol 44, 2159–2166.
13. Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U, Clausen H, Pedersen AE, and Wandall HH (2013). Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 30, 227–236.
14. Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, and van Diest PJ (1999). Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast. Int J Cancer 84, 466–469.
15. Alam M, Rajabi H, Ahmad R, Jin C, and Kufe D (2014). Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget 5, 2622–2634.
16. Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, and Kufe D (2015). Characterization of the MUC1-C cytoplasmic domain as a cancer target. PLoS One 10, e0135156. http://dx.doi.org/10.1371/journal.pone.0135156.
17. Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, and Stieber P (2015). Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta 440, 16–22.
18. Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A, and Nicolai E (2014). CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer 14, 356. http://dx.doi.org/10.1186/1471-2407-14-356.
19. Grzywa R, Lupicka-Slowik A, Walczak M, Idzi M, Bobrek K, Boivin S, Gawel A, Stefaniak T, Oleksyszyn J, and Sienczyk M (2014). Highly sensitive detection of cancer antigen 15-3 using novel avian IgY antibodies. ALTEX 31, 43–52.
20. Curry JM, Thompson KJ, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, and Iannitti DA, et al (2013). The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 107, 713–722.
21. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, and Gong J (2003). Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109, 300–307.
22. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, and Hwang SI, et al (2011). MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30, 1449–1459.
23. Nath S, Roy LD, Grover P, Rao S, and Mukherjee P (2015). Mucin 1 regulates Cox-2 gene in pancreatic cancer. Pancreas 44, 909–917.
24. Hardesty DA, Thind H, Zabramski JM, Spetzler RF, and Nakaji P (2014). Safety, efficacy, and cost of intraoperative indocyanine green angiography compared to intraoperative catheter angiography in cerebral aneurysm surgery. JClinNeurosci21, 1377–1382.
25. Rowse GJ, Ritland SR, and Gendler SJ (1998). Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res 58, 2675–2679.
26. Guy CT, Cardiff RD, and Muller WJ (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954–961.
27. Fluck MM and Schaffhausen BS (2009). Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 73, 542–563.
28. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, and Akslen LA, et al (2000). Molecular portraits of human breast tumours. Nature 406, 747–752.
29. Sorlie T (2007). Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 360, 91–114.
30. Norum JH, Andersen K, and Sorlie T (2014). Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. BrJSurg101,925–938.
31. Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, and Evans SB (2016). Influence of a 21-gene recurrence score assay on chemotherapy delivery in breast cancer. Clin Breast Cancer 16,59–62.
32. Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, and Lieberman N (2013). The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor– positive breast cancer patients. Breast Cancer Res Treat 140, 83–92.
33. Cobain EF and Hayes DF (2015). Indications for prognostic gene expression profiling in early breast cancer. Curr Treat Options Oncol 16, 23. http://dx.doi.org/10.1007/s11864-015-0340-x.
34. McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, and Kerin MJ (2014). The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 50, 2763–2770.
35. Retsky M, Demicheli R, and Hrushesky W (2003). Breast cancer screening: controversies and future directions. Curr Opin Obstet Gynecol 15, 1–8.
36. Nicolini A, Carpi A, and Tarro G (2006). Biomolecular markers of breast cancer. Front Biosci 11, 1818–1843.
37. Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, and Di Gioia D (2015). Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—a retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta 448, 228–231.
38. Debald M, Abramian A, Nemes L, Dobler M, Kaiser C, Keyver-Paik MD, Leutner C, Holler T, Braun M, and Kuhl C, et al (2015). Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer. Breast Cancer Res Treat 153, 531–537.
39. Goldenberg DM and Nabi HA (1999). Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 29, 41–48.
40. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, and Sevick-Muraca EM (2007). Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 48, 1501–1510.
41. Lutje S, Rijpkema M, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ, Colombatti M, and Boerman OC (2014). Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody. J Nucl Med 55, 995–1001.
42. Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, and van Weerden WM (2015). A novel (1)(1)(1)In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med 56, 1094–1099.
43. Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, Quintero AM, De Toma G, Manfrini S, and Pozzilli P (2015). Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care 38, 652–658.
44. Chetlen A, Mack J, and Chan T (2016). Breast cancer screening controversies: who, when, why, and how? Clin Imaging 40, 279–282.
45. Rosso A, Lang K, Petersson IF, and Zackrisson S (2015). Factors affecting recall rate and false positive fraction in breast cancer screening with breast tomosynthesis—a statistical approach. Breast 24, 680–686.
46. Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, and Vachon CM (2015). Awareness of breast density and its impact on breast cancer detection and risk. J Clin Oncol 33, 1143–1150.
47. Kemp Jacobsen K, O'Meara ES, Key D, D S M Buistd, Kerlikowske K, Vejborg I, Sprague BL, Lynge E, and von Euler-Chelpin M (2015). Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer 137, 2198–2207.
48. Slanetz PJ, Freer PE, and Birdwell RL (2015). Breast-density legislation— practical considerations. N Engl J Med 372, 593–595.